Pfizer and Allergan are considering putting Brent Saunders in charge of the company that would be created by their merger, Bloomberg News is reporting.
Saunders is currently CEO of Allergan, which Pfizer is in talks to acquire. A deal, which could be the largest of 2015, may be reached by Thanksgiving, Bloomberg says, citing unidentified sources.
The 45-year-old Saunders was CEO of Allergan when it was acquired by Actavis. He took over the combined company, which was named Allergan Plc in March.
If all goes according to these plans, Saunders would take on the role instead of 62-year-0ld Pfizer CEO Ian Read, who has been in that position since 2010, Bloomberg said.
The full Bloomberg report, by Matthew Campbell, Ruth David and Cynthia Koons, is here.
We’ve reached out to Pfizer and Allergan for comment, and we’ll update if we hear back.
NOW WATCH: One of the world’s rarest species of whale has been caught on camera for the first time ever
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.